{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:19:58Z","timestamp":1787066398185,"version":"build-2736575974"},"reference-count":69,"publisher":"Spandidos Publications","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,10]]},"DOI":"10.3892\/br.2017.977","type":"journal-article","created":{"date-parts":[[2017,9,5]],"date-time":"2017-09-05T03:13:42Z","timestamp":1504581222000},"page":"370-376","source":"Crossref","is-referenced-by-count":13,"title":["Prevalence of the Janus kinase 2 V617F mutation in Philadelphia-negative myeloproliferative neoplasms in a Portuguese population"],"prefix":"10.3892","volume":"7","author":[{"given":"Ana Paula","family":"Azevedo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana N.","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Reichert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando","family":"Lima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esmeraldina","family":"J\u00fanior","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9","family":"Rueff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2249","published-online":{"date-parts":[[2017,9,5]]},"reference":[{"key":"key20180107142100_b1-br-0-0-977","volume-title":"WHO Classification of Tumours of Haematopioetic and Lymphoid Tissues","author":"Swerdlow","year":"2008"},{"key":"key20180107142100_b2-br-0-0-977","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood"},{"key":"key20180107142100_b3-br-0-0-977","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/ajh.23690","article-title":"How common are myeloproliferative neoplasms? A systematic review and meta-analysis","volume":"89","author":"Titmarsh","year":"2014","journal-title":"Am J Hematol"},{"key":"key20180107142100_b4-br-0-0-977","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/ejh.12256","article-title":"Epidemiology of myelofibrosis, essential thrombocythemia, and polycythemia vera in the European Union","volume":"92","author":"Moulard","year":"2014","journal-title":"Eur J Haematol"},{"key":"key20180107142100_b5-br-0-0-977","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1182\/asheducation-2011.1.208","article-title":"Genetic and epigenetic complexity in myeloproliferative neoplasms","volume":"2011","author":"Cross","year":"2011","journal-title":"Hematology (Am Soc Hematol Educ Program)"},{"key":"key20180107142100_b6-br-0-0-977","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1001\/jamaoncol.2015.89","article-title":"Myeloproliferative Neoplasms: A Contemporary Review","volume":"1","author":"Tefferi","year":"2015","journal-title":"JAMA Oncol"},{"key":"key20180107142100_b7-br-0-0-977","first-page":"859","article-title":"JAK2-v617F mutation is associated with clinical and laboratory features of myeloproliferative neoplasms","volume":"36","author":"Duleti\u0107","year":"2012","journal-title":"Coll Antropol"},{"key":"key20180107142100_b8-br-0-0-977","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1038\/sj.leu.2404955","article-title":"Classification and diagnosis of myeloproliferative neoplasms: The 2008 World Health Organization criteria and point-of-care diagnostic algorithms","volume":"22","author":"Tefferi","year":"2008","journal-title":"Leukemia"},{"key":"key20180107142100_b9-br-0-0-977","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","article-title":"A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera","volume":"434","author":"James","year":"2005","journal-title":"Nature"},{"key":"key20180107142100_b10-br-0-0-977","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A gain-of-function mutation of JAK2 in myeloproliferative disorders","volume":"352","author":"Kralovics","year":"2005","journal-title":"N Engl J Med"},{"key":"key20180107142100_b11-br-0-0-977","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","article-title":"Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis","volume":"7","author":"Levine","year":"2005","journal-title":"Cancer Cell"},{"key":"key20180107142100_b12-br-0-0-977","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)74230-6","article-title":"Cancer Genome Project: Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders","volume":"365","author":"Baxter","year":"2005","journal-title":"Lancet"},{"key":"key20180107142100_b13-br-0-0-977","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1056\/NEJMoa065202","article-title":"JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis","volume":"356","author":"Scott","year":"2007","journal-title":"N Engl J Med"},{"key":"key20180107142100_b14-br-0-0-977","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1312542","article-title":"Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2","volume":"369","author":"Nangalia","year":"2013","journal-title":"N Engl J Med"},{"key":"key20180107142100_b15-br-0-0-977","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.beha.2009.08.006","article-title":"Mechanisms of mutations in myeloproliferative neoplasms","volume":"22","author":"Levine","year":"2009","journal-title":"Best Pract Res Clin Haematol"},{"key":"key20180107142100_b16-br-0-0-977","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1182\/blood-2015-06-652941","article-title":"Germ line variants predispose to both JAK2 V617F clonal hematopoiesis and myeloproliferative neoplasms","volume":"128","author":"Hinds","year":"2016","journal-title":"Blood"},{"key":"key20180107142100_b17-br-0-0-977","doi-asserted-by":"crossref","first-page":"3714","DOI":"10.1182\/blood-2014-03-530865","article-title":"From Janus kinase 2 to calreticulin: The clinically relevant genomic landscape of myeloproliferative neoplasms","volume":"123","author":"Cazzola","year":"2014","journal-title":"Blood"},{"key":"key20180107142100_b18-br-0-0-977","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1586\/ehm.10.28","article-title":"JAK2 V617F and beyond: Role of genetics and aberrant signaling in the pathogenesis of myeloproliferative neoplasms","volume":"3","author":"Oh","year":"2010","journal-title":"Expert Rev Hematol"},{"key":"key20180107142100_b19-br-0-0-977","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1016\/j.leukres.2006.01.016","article-title":"Influence of genetic polymorphisms on the risk of developing leukemia and on disease progression","volume":"30","author":"Bolufer","year":"2006","journal-title":"Leuk Res"},{"key":"key20180107142100_b20-br-0-0-977","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s12185-010-0530-z","article-title":"Molecular aspects of myeloproliferative neoplasms","volume":"91","author":"Delhommeau","year":"2010","journal-title":"Int J Hematol"},{"key":"key20180107142100_b21-br-0-0-977","doi-asserted-by":"crossref","first-page":"2891","DOI":"10.1182\/blood-2009-08-236596","article-title":"Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasm","volume":"115","author":"Beer","year":"2010","journal-title":"Blood"},{"key":"key20180107142100_b22-br-0-0-977","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1038\/leu.2008.229","article-title":"JAK2 and MPL mutations in myeloproliferative neoplasms: Discovery and science","volume":"22","author":"Kilpivaara","year":"2008","journal-title":"Leukemia"},{"key":"key20180107142100_b23-br-0-0-977","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.beha.2014.07.003","article-title":"Leukemic transformation in myeloproliferative neoplasms: Therapy-related or unrelated?","volume":"27","author":"Bj\u00f6rkholm","year":"2014","journal-title":"Best Pract Res Clin Haematol"},{"key":"key20180107142100_b24-br-0-0-977","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-1-4939-3347-1_1","article-title":"Cancer Drug Resistance: A Brief Overview from a Genetic Viewpoint","volume":"1395","author":"Rueff","year":"2016","journal-title":"Methods Mol Biol"},{"key":"key20180107142100_b25-br-0-0-977","doi-asserted-by":"crossref","first-page":"e40","DOI":"10.1038\/bcj.2011.39","article-title":"Analysis of genomic aberrations and gene expression profiling identifies novel lesions and pathways in myeloproliferative neoplasms","volume":"1","author":"Rice","year":"2011","journal-title":"Blood Cancer J"},{"key":"key20180107142100_b26-br-0-0-977","doi-asserted-by":"crossref","first-page":"150","DOI":"10.5581\/1516-8484.20120035","article-title":"Molecular biology of Philadelphia-negative myeloproliferative neoplasms","volume":"34","author":"Campregher","year":"2012","journal-title":"Rev Bras Hematol Hemoter"},{"key":"key20180107142100_b27-br-0-0-977","first-page":"11555","article-title":"Prevalence of the frequency of JAK2 (V617F) mutation in different myeloproliferative disorders in Egyptian patients","volume":"8","author":"Ebid","year":"2015","journal-title":"Int J Clin Exp Pathol"},{"key":"key20180107142100_b28-br-0-0-977","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1177\/1947601910397187","article-title":"Jak\/STAT pathways in cytokine signaling and myeloproliferative disorders: Approaches for targeted therapies","volume":"1","author":"Jatiani","year":"2010","journal-title":"Genes Cancer"},{"key":"key20180107142100_b29-br-0-0-977","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1182\/blood-2010-12-327593","article-title":"Effects of the JAK2 mutation on the hematopoietic stem and progenitor compartment in human myeloproliferative neoplasms","volume":"118","author":"Anand","year":"2011","journal-title":"Blood"},{"key":"key20180107142100_b30-br-0-0-977","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/bs.pmbts.2016.09.004","article-title":"Myeloproliferative Neoplasms: Molecular Drivers and Therapeutics","volume":"144","author":"Reuther","year":"2016","journal-title":"Prog Mol Biol Transl Sci"},{"key":"key20180107142100_b31-br-0-0-977","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1038\/sj.leu.2404206","article-title":"JAK2 V617F is a rare finding in de novo acute myeloid leukemia, but STAT3 activation is common and remains unexplained","volume":"20","author":"Steensma","year":"2006","journal-title":"Leukemia"},{"key":"key20180107142100_b32-br-0-0-977","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1101\/cshperspect.a006080","article-title":"Cell Death Signaling","volume":"7","author":"Green","year":"2015","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"key20180107142100_b33-br-0-0-977","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1182\/asheducation-2014.1.268","article-title":"How does JAK2V617F contribute to the pathogenesis of myeloproliferative neoplasms?","volume":"2014","author":"Chen","year":"2014","journal-title":"Hematology (Am Soc Hematol Educ Program)"},{"key":"key20180107142100_b34-br-0-0-977","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.3324\/haematol.2015.128546","article-title":"STAT1 activation in association with JAK2 exon 12 mutations","volume":"101","author":"Godfrey","year":"2016","journal-title":"Haematologica"},{"key":"key20180107142100_b35-br-0-0-977","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.1182\/blood-2010-11-316810","article-title":"Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations","volume":"117","author":"Passamonti","year":"2011","journal-title":"Blood"},{"key":"key20180107142100_b36-br-0-0-977","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.3324\/haematol.2014.107631","article-title":"JAK2V617F somatic mutation in the general population: Myeloproliferative neoplasm development and progression rate","volume":"99","author":"Nielsen","year":"2014","journal-title":"Haematologica"},{"key":"key20180107142100_b37-br-0-0-977","doi-asserted-by":"crossref","first-page":"385","DOI":"10.3343\/alm.2012.32.6.385","article-title":"Correlations between Janus kinase 2 V617F allele burdens and clinicohematologic parameters in myeloproliferative neoplasms","volume":"32","author":"Ha","year":"2012","journal-title":"Ann Lab Med"},{"key":"key20180107142100_b38-br-0-0-977","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1111\/j.1600-0609.2007.00960.x","article-title":"The JAK2 V617F allele burden in essential thrombocythemia, polycythemia vera and primary myelofibrosis - impact on disease phenotype","volume":"79","author":"Larsen","year":"2007","journal-title":"Eur J Haematol"},{"key":"key20180107142100_b39-br-0-0-977","doi-asserted-by":"crossref","first-page":"e369","DOI":"10.1038\/bcj.2015.94","article-title":"Practice-relevant revision of IPSET-thrombosis based on 1019 patients with WHO-defined essential thrombocythemia","volume":"5","author":"Barbui","year":"2015","journal-title":"Blood Cancer J"},{"key":"key20180107142100_b40-br-0-0-977","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1177\/2040620710394474","article-title":"JAK2 Allele Burden in the Myeloproliferative Neoplasms: Effects on Phenotype, Prognosis and Change with Treatment","volume":"2","author":"Vannucchi","year":"2011","journal-title":"Ther Adv Hematol"},{"key":"key20180107142100_b41-br-0-0-977","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1038\/leu.2014.76","article-title":"The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: An international study of 797 patients","volume":"28","author":"Guglielmelli","year":"2014","journal-title":"Leukemia"},{"key":"key20180107142100_b42-br-0-0-977","doi-asserted-by":"crossref","first-page":"2601","DOI":"10.1038\/onc.2012.347","article-title":"JAK\/STAT signaling in hematological malignancies","volume":"32","author":"Vainchenker","year":"2013","journal-title":"Oncogene"},{"key":"key20180107142100_b43-br-0-0-977","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1038\/bjc.2015.233","article-title":"The role of JAK\/STAT signalling in the pathogenesis, prognosis and treatment of solid tumours","volume":"113","author":"Thomas","year":"2015","journal-title":"Br J Cancer"},{"key":"key20180107142100_b44-br-0-0-977","doi-asserted-by":"crossref","first-page":"450","DOI":"10.3324\/haematol.2010.033191","article-title":"The JAK2 V617F somatic mutation, mortality and cancer risk in the general population","volume":"96","author":"Nielsen","year":"2011","journal-title":"Haematologica"},{"key":"key20180107142100_b45-br-0-0-977","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1080\/15321819.2016.1152276","article-title":"A link between the driver mutations and dysregulated apoptosis in BCR-ABL1 negative myeloproliferative neoplasms","volume":"37","author":"Mambet","year":"2016","journal-title":"J Immunoassay Immunochem"},{"key":"key20180107142100_b46-br-0-0-977","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1002\/ajh.24607","article-title":"Polycythemia vera and essential thrombocythemia: 2017 update on diagnosis, risk-stratification, and management","volume":"92","author":"Tefferi","year":"2017","journal-title":"Am J Hematol"},{"key":"key20180107142100_b47-br-0-0-977","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1002\/ajh.24221","article-title":"Myeloproliferative neoplasms: A decade of discoveries and treatment advances","volume":"91","author":"Tefferi","year":"2016","journal-title":"Am J Hematol"},{"key":"key20180107142100_b48-br-0-0-977","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.hoc.2017.04.002","article-title":"The Development and Use of Janus Kinase 2 Inhibitors for the Treatment of Myeloproliferative Neoplasms","volume":"31","author":"Hobbs","year":"2017","journal-title":"Hematol Oncol Clin North Am"},{"key":"key20180107142100_b49-br-0-0-977","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1182\/blood-2016-10-695965","article-title":"Emerging treatments for classical myeloproliferative neoplasms","volume":"129","author":"Vannucchi","year":"2017","journal-title":"Blood"},{"key":"key20180107142100_b50-br-0-0-977","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1080\/17474086.2017.1317590","article-title":"Management of myelofibrosis: JAK inhibition and beyond","volume":"10","author":"Stahl","year":"2017","journal-title":"Expert Rev Hematol"},{"key":"key20180107142100_b51-br-0-0-977","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.cdp.2007.07.001","article-title":"Menopausal age and XRCC1 gene polymorphisms: Role in breast cancer risk","volume":"31","author":"Silva","year":"2007","journal-title":"Cancer Detect Prev"},{"key":"key20180107142100_b52-br-0-0-977","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1089\/thy.2009.0099","article-title":"Association of polymorphisms in genes of the homologous recombination DNA repair pathway and thyroid cancer risk","volume":"19","author":"Bastos","year":"2009","journal-title":"Thyroid"},{"key":"key20180107142100_b53-br-0-0-977","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1186\/1471-2407-9-344","article-title":"Association of common variants in mismatch repair genes and breast cancer susceptibility: A multigene study","volume":"9","author":"Conde","year":"2009","journal-title":"BMC Cancer"},{"key":"key20180107142100_b54-br-0-0-977","first-page":"1079","article-title":"The role of common variants of non-homologous end-joining repair genes XRCC4, LIG4 and Ku80 in thyroid cancer risk","volume":"24","author":"Gomes","year":"2010","journal-title":"Oncol Rep"},{"key":"key20180107142100_b55-br-0-0-977","first-page":"593","article-title":"The role of GSTA2 polymorphisms and haplotypes in breast cancer susceptibility: A case-control study in the Portuguese population","volume":"22","author":"Silva","year":"2009","journal-title":"Oncol Rep"},{"key":"key20180107142100_b56-br-0-0-977","doi-asserted-by":"crossref","first-page":"1928","DOI":"10.1093\/bioinformatics\/btl268","article-title":"SNPStats: A web tool for the analysis of association studies","volume":"22","author":"Sol\u00e9","year":"2006","journal-title":"Bioinformatics"},{"key":"key20180107142100_b57-br-0-0-977","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1182\/blood-2016-10-695957","article-title":"Diagnosis, risk stratification, and response evaluation in classical myeloproliferative neoplasms","volume":"129","author":"Rumi","year":"2017","journal-title":"Blood"},{"key":"key20180107142100_b58-br-0-0-977","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1182\/blood-2005-03-1320","article-title":"Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders","volume":"106","author":"Jones","year":"2005","journal-title":"Blood"},{"key":"key20180107142100_b59-br-0-0-977","doi-asserted-by":"crossref","first-page":"2213","DOI":"10.1084\/jem.20131371","article-title":"Myeloproliferative neoplasms can be initiated from a single hematopoietic stem cell expressing JAK2-V617F","volume":"211","author":"Lundberg","year":"2014","journal-title":"J Exp Med"},{"key":"key20180107142100_b60-br-0-0-977","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1038\/sj.leu.2404971","article-title":"Two novel JAK2 exon 12 mutations in JAK2V617F-negative polycythaemia vera patients","volume":"22","author":"Butcher","year":"2008","journal-title":"Leukemia"},{"key":"key20180107142100_b61-br-0-0-977","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1136\/jclinpath-2016-203649","article-title":"High frequency of JAK2 exon 12 mutations in Korean patients with polycythaemia vera: Novel mutations and clinical significance","volume":"69","author":"Park","year":"2016","journal-title":"J Clin Pathol"},{"key":"key20180107142100_b62-br-0-0-977","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1038\/leu.2010.148","article-title":"A prospective study of 338 patients with polycythemia vera: The impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications","volume":"24","author":"Passamonti","year":"2010","journal-title":"Leukemia"},{"key":"key20180107142100_b63-br-0-0-977","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1182\/blood-2013-11-539098","article-title":"Associazione Italiana per la Ricerca sul Cancro Gruppo Italiano Malattie Mieloproliferative Investigators: JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes","volume":"123","author":"Rumi","year":"2014","journal-title":"Blood"},{"key":"key20180107142100_b64-br-0-0-977","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1002\/ajh.22063","article-title":"The JAK2 exon 12 mutations: A comprehensive review","volume":"86","author":"Scott","year":"2011","journal-title":"Am J Hematol"},{"key":"key20180107142100_b65-br-0-0-977","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1111\/j.1365-2141.2007.06806.x","article-title":"Prevalance of JAK2 V617F and exon 12 mutations in polycythaemia vera","volume":"139","author":"Scott","year":"2007","journal-title":"Br J Haematol"},{"key":"key20180107142100_b66-br-0-0-977","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1038\/sj.leu.2404810","article-title":"Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera","volume":"21","author":"Pardanani","year":"2007","journal-title":"Leukemia"},{"key":"key20180107142100_b67-br-0-0-977","doi-asserted-by":"crossref","first-page":"4641","DOI":"10.3892\/ol.2017.6065","article-title":"DNA repair genes polymorphisms and genetic susceptibility to Philadelphia-negative myeloproliferative neoplasms in a Portuguese population: The role of base excision repair genes polymorphisms","volume":"13","author":"Azevedo","year":"2017","journal-title":"Oncol Lett"},{"key":"key20180107142100_b68-br-0-0-977","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1111\/ejh.12684","article-title":"Smoking and philadelphia-negative chronic myeloproliferative neoplasms","volume":"97","author":"Lindholm","year":"2015","journal-title":"Eur J Haematol"},{"key":"key20180107142100_b69-br-0-0-977","first-page":"30373","article-title":"Smoking as a contributing factor for development of polycythemia vera and related neoplasms","volume":"15","author":"Hasselbalch","year":"2015","journal-title":"Leuk Res"}],"container-title":["Biomedical Reports"],"original-title":[],"language":"en","deposited":{"date-parts":[[2019,10,3]],"date-time":"2019-10-03T00:13:00Z","timestamp":1570061580000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.spandidos-publications.com\/10.3892\/br.2017.977"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,9,5]]},"references-count":69,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2017,9,5]]},"published-print":{"date-parts":[[2017,10]]}},"alternative-id":["10.3892\/br.2017.977"],"URL":"https:\/\/doi.org\/10.3892\/br.2017.977","relation":{},"ISSN":["2049-9434","2049-9442"],"issn-type":[{"value":"2049-9434","type":"print"},{"value":"2049-9442","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,9,5]]}}}